Haemoglobin level and vascular access survival in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 20, Issue 11, 2005, Pages 2453-2457

  Garrancho, José M ^a   Kirchgessner, Judith ^b   Arranz, Mariana ^a   Klinkner, Gerdi ^b   Rentero, Ramón ^a   Ayala, Juan A ^a   Marcelli, Daniele ^b  

^a Fresenius Medical Care Spain   (Spain)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

ACE inhibitors; Anemia correction; Diabetes mellitus; Haemoglobin; iPTH; Vascular access

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGE; AGED; ANEMIA; ARTERIOVENOUS FISTULA; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENDER; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTECTION; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOSIS; VASCULAR ACCESS; VASCULAR DISEASE;

AGED; ARTERIOVENOUS SHUNT, SURGICAL; BIOLOGICAL MARKERS; CATHETERS, INDWELLING; EQUIPMENT FAILURE; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 27644435129     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi027     Document Type: Article

References (14)

1. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 [Suppl 5]: 1-50
2. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: Update 2000. Am J Kidney Dis 2001; 37 [1 Suppl 1]: S137-S181
3. Furuland H, Linde T, Ahlmen J et al. A randomised controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361
4. Harnett JD, Kent GM, Foley RN et al. Cardiac function and hematocrit level. Am J Kidney Dis 1995; 25 [4 Suppl 1]: S3-S7
5. Pickett JL, Theberge DC, Brown WS et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999; 33: 1122-1130
6. Collins AJ, Li S, St Peter W et al. Death, hospitalization, and economic associations among incident haemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-2473
7. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving haemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
8. Marcelli D, Kirchgessner J, Amato C et al. EuCliD (European Clinical Database): A database comparing different realities. J Nephrol 2001; 14 [Suppl 4]: S94-S101
9. Marcelli D, Moscardó V, Steil H et al. Data management and Quality Assurance for Dialysis Network. Contrib Nephrol 2002; 137: 293-299
10. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000; 36: 68-74
11. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
12. Grandaliano G, Teutonico A, Allegretti A et al. The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in haemodialysis. Kidney Int 2003; 64: 715-719
13. Saran R, Dykstra DM, Wolfe RA et al. Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Dialysis Outcomes and Practice Patterns Study. Am J Kidney Dis 2002; 40: 1255-1263
14. Gradzki R, Dhingra RK, Port FK et al. Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001; 38: 1240-1244